37182-75-5

Basic information

• Product Name: 1-(3-CARBOXYPHENYL)-2-THIOUREA
• Synonyms: 1-(3-CARBOXYPHENYL)-2-THIOUREA;3-[(AMINOCARBOTHIOYL)AMINO]BENZOIC ACID;3-[(AMINOCARBONOTHIOYL)AMINO]BENZOIC ACID;RARECHEM AL BO 0602;1-(3-Carboxyphenyl)-2-thiourea 96%;3-(carbamothioylamino)benzoic acid
• CAS NO: 37182-75-5
• Molecular Formula: C₈H₈N₂O₂S
• Molecular Weight: 196.23
• Product Categories: Organic Building Blocks;Sulfur Compounds;Thioureas;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfur Compounds
• Mol File: 37182-75-5.mol
• Article Data: 15

Chemical Properties

• Melting Point: 187-191 °C(lit.)
• Boiling Point: 399.8 °C at 760 mmHg
• Flash Point: 195.6 °C
• Appearance: /
• Density: 1.508 g/cm³
• Vapor Pressure: 4.14E-07mmHg at 25°C
• CAS DataBase Reference: 1-(3-CARBOXYPHENYL)-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-CARBOXYPHENYL)-2-THIOUREA(37182-75-5)
• EPA Substance Registry System: 1-(3-CARBOXYPHENYL)-2-THIOUREA(37182-75-5)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 37182-75-5(Hazardous Substances Data)

Usage

Uses

1-(3-Carboxyphenyl)-2-thiourea functionalized mesoporous silica SBA-15 (CPTU-SBA-15) has been used for the solid phase extraction of Hg(II).

General Description

1-(3-Carboxyphenyl)-2-thiourea (CPTU) is a thiourea derivative containing electron donor atoms (N and S). It acts as a ligand and readily form complexes with Hg(II).

InChI:InChI=1/C8H8N2O2S/c9-8(13)10-6-3-1-2-5(4-6)7(11)12/h1-4H,(H,11,12)(H3,9,10,13)/p-1

Upstream product

• 192948-00-8 methyl 3-thioureidobenzoate 
• 1147550-11-5 ammonium thiocyanate 
• 99-05-8 meta-aminobenzoic acid 
• 2131-63-7 3-isothiocyanatobenzoic acid 
• 183430-27-5 3-cyanoamino-benzoic acid 
• 333-20-0 potassium thioacyanate 
• 433704-66-6 3-(3-benzoylthioureido)benzoic acid 

Downstream Products

• 183430-27-5 3-cyanoamino-benzoic acid 
• 71224-95-8 2-aminobenzo[d]thiazole-7-carboxylic acid 
• 188812-29-5 N-(3-carboxyphenyl)-S-methylthiourea hydroiodide 

Relevant articles and documents

ALPHA-5 BETA-1 INHIBITORS

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach ?

Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR). In addition to respiratory impairment due to mucus accumulation, viruses and bacteria trigger acute pulmonary exacerbations, accelerating disease progression and mortality rate. Treatment complexity increases with patients' age, and simplifying the therapeutic regimen represents one of the key priorities in CF. We have recently reported the discovery of multitarget compounds able to "kill two birds with one stone" by targeting F508del-CFTR and PI4KIIIβ and thus acting simultaneously as CFTR correctors and broad-spectrum enterovirus (EV) inhibitors. Starting from these preliminary results, we report herein a hit-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to compound 23a. This compound showed good antiviral and F508del-CFTR correction potency, additivity/synergy with lumacaftor, and a promising in vitro absorption, distribution, metabolism, and excretion (ADME) profile. It was well tolerated in vivo with no sign of acute toxicity and histological alterations in key biodistribution organs.

Thiazole aminobenzoic acid derivatives and use thereof (by machine translation)

The invention discloses a have anti-tumor activity of the thiazole aminobenzoic acid derivative, it can be used for the preparation of anticancer drugs, in particular as Bcr - Abl tyrosine kinase inhibitors, in particular can be used as a T315I mutant Bcr